EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Access Bio's enterprise value is ₩-59,695 Mil.
Access Bio's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-38,685 Mil. Therefore, Access Bio's EV-to-EBITDA for today is 1.54.
The historical rank and industry rank for Access Bio's EV-to-EBITDA or its related term are showing as below:
XKRX:950130'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -538.28 Med: 1.92 Max: 631.71
Current: 1.55
During the past 12 years, the highest EV-to-EBITDA of Access Bio was 631.71. The lowest was -538.28. And the median was 1.92.
XKRX:950130's EV-to-EBITDA is ranked better than 91.96% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.625
vs XKRX:950130: 1.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-23), Access Bio's stock price is ₩7020.00.
Access Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-1243.000. Therefore, Access Bio's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Access Bio EV-to-EBITDA Historical Data
The historical data trend for Access Bio's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Access Bio's EV-to-EBITDA
For the Diagnostics & Research subindustry, Access Bio's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Access Bio's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Access Bio's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Access Bio's EV-to-EBITDA falls into.
Access Bio EV-to-EBITDA Calculation
Access Bio's EV-to-EBITDA for today is calculated as:
Access Bio's current Enterprise Value is ₩-59,695 Mil.
Access Bio's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-38,685 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Access Bio (XKRX:950130) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Access Bio's share price for today is ₩7020.00.
Access Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-1243.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Access Bio's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:950130 has been successfully added to your 